1) Bonetti A, et al : Cisplatin Pharmacokinetics Using a Five-Day Schedule During Repeated Courses of Chemotherapy in Germ Cell Tumors. Ther Drug Monit, 17 : 25-32, 1995
2) Albany C, et al : Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens : A Hoosier Oncology Group Study. J Clin Oncol, 30 : 3998-4003, 2012
3) Sekine I, et al : Risk factors of chemotherapy-induced nausea and vomiting : index for personalized antiemetic prophylaxis. Cancer Sci, 104 : 711-717, 2013
4) Dranitsaris G, et al : The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol, 28 : 1260-1267, 2017
5) Scotte F : Identifying predictive factors of chemotherapy-induced nausea and vomiting (CINV) : a novel approach. Ann Oncol, 28 : 1165-1167, 2017
6) Ioannidis JP, et al. Contribution of Dexamethasone to Control of Chemotherapy-Induced Nausea and Vomiting : A Meta-Analysis of Randomized Evidence. J Clin Oncol, 18 : 3409-3422, 2000
7) Vardy J, et al : Side Effects Associated With the Use of Dexamethasone for Prophylaxis of Delayed Emesis After Moderately Emetogenic Chemotherapy. Br J Cancer, 94 : 1011-1015, 2006
8) Nakamura M, et al : A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01). Oncologist, 22 : 592-600, 2017
9) Jeong Y, et al : A Pilot Study Evaluating Steroid-Induced Diabetes After Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients. Cancer Res Treat, 48 : 1429-1437, 2016
10) Celio L, et al : Palonosetron in Combination With 1-day Versus 3-day Dexamethasone for Prevention of Nausea and Vomiting Following Moderately Emetogenic Chemotherapy : A Randomized, Multicenter, Phase III Trial. Support Care Cancer, 19 : 1217-1225, 2011
11) Aapro M, et al : Double-blind, Randomised, Controlled Study of the Efficacy and Tolerability of Palonosetron Plus Dexamethasone for 1 day With or Without Dexamethasone on days 2 and 3 in the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy. Ann Oncol, 21 : 1083-1088, 2010
12) Komatsu Y, et al : Open-label, Randomized, Comparative, Phase III Study on Effects of Reducing Steroid Use in Combination With Palonosetron. Cancer Sci, 106 : 891-895, 2015
13) Ito Y, et al : Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on day 1 With Dexamethasone on days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy. J Clin Oncol, 36 : 1000-1006, 2018
14) Tamura K, et al : Testing the Effectiveness of Antiemetic Guidelines : Results of a Prospective Registry by the CINV Study Group of Japan. Int J Clin Oncol, 20 : 855-865, 2015
15) Navo M, et al : Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol, 103 : 608-613, 2006
16) Sliesoraitis S, et al : Carboplatin hypersensitivity. Int J Gynecol Cancer, 15 : 13-18, 2005
17) 西尾真, 他 : カルボプラチンの過敏正反応に対し脱感作投与法にてカルボプラチンを安全に再投与し得た再発卵巣癌の1例. 癌と化学療法, 37 : 731-733, 2010
18) 樋野光生, 他 : 塩酸ゲムシタビン投与中に起こる血管痛の評価とその対策. 日本病院薬剤師会雑誌, 44 : 801-803, 2008
19) Xu Q, et al : Physical and chemical stability of gemcitabine hydrochloride solutions. J Am Pharm Assoc, 39 : 509-513, 1999
20) 松山和代, 他 : Oxaliplatin 末梢投与における血管痛の原因と対策. 癌と化学療法, 38 : 411-414, 2011
21) Watanabe H, et al : Decrease in venous irritation by adjusting the concentration of injected bendamustine, Biol Pharm Bull, 36 : 574-578, 2013
22) 上野千奈美, 他 : パクリタキセル注投与時におけるd-クロルフェニラミンマレイン酸塩注射液によるアレルギー反応の予防効果. 医療薬学, 35 : 825-829, 2009
23) 原田知彦, 他 : Paclitaxel注の急性過敏症反応に対するd-マレイン酸クロルフェニラミン注を用いたShort-Time Premedicationの検討. 癌と化学療法, 35 : 1347-1351, 2008
24) 大塚知信, 他 : FOLFOX 療法におけるオキサリプラチン注射薬の安定性, 医療薬学, 32 : 1027-1032, 2006
25) Mizuta, et al : Compatibility and stability of nab-paclitaxel in combination with other drugs. Kobe J Med Sci, 63 : E9-E16, 2017
26) 河原昌美, 他 : Dacarbazineの光分解によって生成する発痛物質の探索. 臨床薬理, 32 : 15-22, 2001
27) 辻琢己, 他 : ダカルバジン投与時に生じる血管痛の抑制を目的とした投与方法. YAKUGAKU ZASSHI, 134 : 981-986, 2014
28) 大坪達弥, 他 : ダカルバジン投与における血管痛対策の検討. YAKUGAKU ZASSHI, 137 : 363-369, 2017
29) Mangili G, et al : Prevention Strategies in Palmar-Plantar Erythrodysesthesia Onset : The Role of Regional Cooling. Gynecol Oncol, 108 : 332-335, 2008
30) Burris HA, et al : Pegfilgrastim on the Same day Versus Next day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma : Results of Four Multicenter, Double-Blind, Randomized Phase II Studies. J Oncol Pract, 6 : 133-140, 2010
31) Weycker D, et al : Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis : does timing of administration matter? Support Care Cancer, 24 : 2309-2316, 2016
32) Lambertini M, et al : Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline-and taxane-based chemotherapy in breast cancer patients : a single-center experience within the GIM2 randomized phase III trial. Support Care Cancer, 24 : 1285-1294, 2016
33) Hayama T, et al : Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies. Int J Clin Pharm, 40 : 997-1000, 2018
34) Harland SJ, et al : Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res, 44 : 1693-1697, 1984
35) Calvert AH, et al : Phase I studies with carboplatin at The Royal Marsden Hospital. Cancer Treat Rev, 12 : 51-57, 1985
36) Calvert AH, et al : Carboplatin dosage : prospective evaluation of a simple formula based on renal function. J Clin Oncol, 7 : 1748-1756, 1989
37) Jodrell DI, et al : Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol, 10 : 520-528, 1992
38) Horio M, et al : Comparison of Jaffe rate assay and enzymatic method for the measurement of creatinine clearance. Nihon Jionzo Gakkai Shi, 38 : 296-299, 1996
39) Ando M, et al : Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res, 6 : 4733-4738, 2000
40) 「エビデンスに基づくCKD診療ガイドライン 2009」 (日本腎臓学会/編), 東京医学社, pp1-10, 2009
41) Shimokata T, et al : Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Cancer Sci, 101 : 2601-2605, 2010
42) National Institutes of Health National Cancer Institute Bethesda, Maryland 20892, Follow-up for information letter regarding AUC-based dosing of carboplatin. Octover 22, 2010 [https://ctep.cancer.gov/content/docs/Carboplatin_Information_Letter.pdf]
43) Gynecologic Oncology Group, Newsletter Spring 2011 [https://www.gog.org/Spring2011newsletter.pdf]
44) Matsuo S, et al : Collaborators developing the Japanese equation for estimated GFR, Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis, 53 : 982-992, 2009
45) 今村知世, 他 : カルボプラチン投与量算出におけるCalvert式利用に関する実態調査. 医療薬学, 41 : 759-767, 2015
46) Funakoshi Y, et al : Prediction of Glomerular Filtration Rate in Cancer Patients by an Equation for Japanese Estimated Glomerular Filtration Rate. Jpn J Clin Oncol, 43 : 271-277, 2013
47) Funakoshi Y, et al : Validity of New Methods to Evaluate Renal Function in Cancer Patients Treated With Cisplatin. Cancer Chemother Pharmacol, 77 : 281-288, 2016
48) Stevens LA, et al : Assessing Kidney Function--Measured and Estimated Glomerular Filtration Rate. N Engl J Med, 354 : 2473-2483, 2006
49) 医療事故情報収集等事業. 医療安全情報, No.93, 2014年8月